Supernus Pharmaceuticals, Inc. / Financial strength (Piotroski F-Value) /

    The F-Value, developed by Stanford accounting professor Joseph Piotroski, measures a company's financial strength based on nine distinct criteria. Piotroski suggest using the value as part of a value investing strategy to rank stocks with a low price-to-book ratio. The approach is described in detail in Piotroski's 2002 Paper Value Investing: The Use of Historical Financial Statement Information to Separate Winners From Losers.

    You are viewing the F-Value as of . Click to view the current F-Value instead.

    Financial strength (Piotroski F-Value)
    3 / 9
    Return on assets (ROA) greater than 0
    close -55.1%
    Operating cash flow greater than 0
    close -$51.54M
    ROA greater than previous year
    close -55.1% ≤ 66.2%
    Cash flow return on assets (CFROA) greater than Return on assets (ROA)
    check -45.8% > -55.1%
    Leverage ratio lower than previous year
    close 44.8% ≥ 21.3%
    Current ratio greater than previous year
    check 690.3% > 355.6%
    No new common stock issued last year
    close $43.06M
    Gross margin greater than previous year
    close 99.8% ≤ 100.0%
    Asset turnover greater than previous year
    check 1.2% > -11.9%

    F-Value history

    The F-Value is calculated for each quarter based on the cumulation of the previous four quarterly statements. Click on the chart to see the F-Value at a specific time in the past.

    6
    4
    5
    3
    3
    2
    3
    3
    4
    7
    7
    7
    5
    4
    4
    4
    5
    5
    5
    6
    5
    5
    5
    5
    5
    5
    6
    5
    5
    4
    5
    4
    4
    5
    5
    6
    6
    4
    4
    6
    6
    6
    5
    5
    5
    5
    4
    5
    7
    7
    7
    7

    Notifications